PURPOSE: To report a case of contralateral vitritis following intravitreal bevacizumab (Avastin, Roche Pharma). CASE SUMMARY: A 54-year-old man was treated with intravitreal bevacizumab (IB) for a choroidal neovascularization secondary to anisometropic high myopia in the right eye that did not respond to photodynamic treatment. After the second injection, he showed a moderate vitritis in the fellow un-injected eye a few hours later. RESULTS: The patient was treated with a sub-Tenon's injection of 40 mg triamcinolone (Kenacort, Squibb) and entirely recovered his vision. No further complications were observed. DISCUSSION: Although IB has a satisfactory safety profile, the possibility of unusual complications associated with the drug or the procedure itself should always be considered.
PURPOSE: To report a case of contralateral vitritis following intravitreal bevacizumab (Avastin, Roche Pharma). CASE SUMMARY: A 54-year-old man was treated with intravitreal bevacizumab (IB) for a choroidal neovascularization secondary to anisometropic high myopia in the right eye that did not respond to photodynamic treatment. After the second injection, he showed a moderate vitritis in the fellow un-injected eye a few hours later. RESULTS: The patient was treated with a sub-Tenon's injection of 40 mg triamcinolone (Kenacort, Squibb) and entirely recovered his vision. No further complications were observed. DISCUSSION: Although IB has a satisfactory safety profile, the possibility of unusual complications associated with the drug or the procedure itself should always be considered.
Authors: J L Davis; K K Mittal; V Freidlin; S R Mellow; D C Optican; A G Palestine; R B Nussenblatt Journal: Ophthalmology Date: 1990-09 Impact factor: 12.079
Authors: Robert L Avery; Joel Pearlman; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust; Robert Wendel; Arun Patel Journal: Ophthalmology Date: 2006-10 Impact factor: 12.079
Authors: D J Kilmartin; D Wilson; J Liversidge; A D Dick; J Bruce; R W Acheson; S J Urbaniak; J V Forrester Journal: Br J Ophthalmol Date: 2001-03 Impact factor: 4.638